Sustained and expanded financing is needed to safeguard TB research against COVID-19–related disruptions and improve global epidemic preparedness.

TAG and OTMeds call on Sanofi to reverse its efforts to patent two obvious combinations of two critical drugs to prevent TB: rifapentine and isoniazid.

Treatment Action Group launches two new TB Activist Guides: An Activist’s Guide to Tuberculosis Diagnostic Tools, and An Activist’s Guide to Treatment for Drug-Resistant Tuberculosis.

Bedaquiline is a public good, and must be treated as such. Johnson & Johnson once again refused to meet evidence-based demands to price bedaquiline at $1/day.

Treatment Action Group released the May 2020 edition of TAGline, focused on the right to science.

Cutting global health funding in the middle of a pandemic will only prolong the devastating loss of life and economic damage in the U.S. and across the world, and undermine the response to other infectious diseases, including HIV, TB, and hepatitis C.

More research required to determine if century-old TB vaccine protects against SARS-CoV-2 infection or severe COVID-19 disease.

On 3 April 2020, Treatment Action Group (TAG), Médecins Sans Frontières (MSF) Access Campaign, and the Global Coalition of TB Activists (GCTA) held a webinar on the price of Xpert tests for COVID-19, HIV, TB, HCV and other diseases. The webinar provided the latest information about the “Time for $5” campaign and the evidence base for why GeneXpert tests should be priced at US$5.

Cepheid is profiteering during a pandemic, with dangerous consequences for countries with vulnerable populations and health systems.

Treatment Action Group (TAG) released an overview of TB data reported at the 2020 Conference on Retroviruses and Opportunistic Infections (CROI) virtually held on 8-11 March 2020. A summary of major findings, TAG’s take on them, and high-level summaries of select findings are available here.